Post by Lonza

Have you heard about our early de-risking package? Developing a biologics candidate means making critical decisions long before IND-enabling studies begin. Which risks should be addressed first? Which candidates are ready to advance? And what data will help strengthen conversations with investors? In this Q&A, our experts from Lonza's Early Development Services discuss how integrated in silico developability assessments, stable pool protein expression, and in vitro immunogenicity testing can help emerging biotechs identify and address key risks earlier. De-risk the science. Strengthen your IND story. Accelerate the capital. Read the Q&A: https://ow.ly/XCFS50ZnFS9 #Biologics #EarlyDevelopment #INDReadiness #CDMO